Clinical implications of ERb methylation on sporadic breast cancers in Chinese women

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1569-1575

  Zhao, Lin ^a   Yu, Zhaojin ^a   Li, Yunan ^a   Wen, Xiaoyan ^a   Ma, Wenfeng ^a   Wang, Lin ^a   Ren, Jie ^a   Liu, Caigang ^a   He, Miao ^a   Bai, Xuefeng ^a   Sun, Mingli ^a   Zheng, Zhihong ^a   Mi, Xiaoyi ^a   Wang, Enhua ^a   Olopade, Olufunmilayo I ^b   Jin, Feng ^a   Wei, Minjie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Breast cancer; Chinese women; ERb; Methylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; CHINESE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TRIPLE NEGATIVE BREAST CANCER; ASIAN; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; GENE SILENCING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; DNA METHYLATION; ESTROGEN RECEPTOR BETA; FEMALE; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 84872764016     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0107-6     Document Type: Article

References (24)

1. Yang L, Parkin DM, Ferlay J, Li L, Chen YE. stimates of cancer incidencein China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005;14:243-50.
2. Allred DC. Issues and updates: evaluating estrogen receptoralpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 2010;23:52-9.
3. Mosselman S, Polman J, Dijkema R. ERb: identification and characterisation of a novel human estrogen receptor. FEBS Lett. 1996;392:49-53.
4. Jensen EV, Jacobson HI, Walf AA, et al. Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol Behav. 2010;99:151-62.
5. Bardin A, Boulle N, Lazennec G, et al. Loss of ER beta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11:537-51.
6. Fox EM, Davis RJ, Shupnik MA. ERbeta in breast cancer-onlooker, passive player, or active protector? Steroids. 2008;73: 1039-51.
7. Roger P, Sahla ME, Mäkelä S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61:2537-41.
8. Swedenborg E, Power KA, Cai W, et al. Regulation of estrogen receptor beta activity and implications in health and disease. Cell Mol Life Sci. 2009;66:3873-94.
9. Xu X, Gammon MD, Zhang Y, et al. Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat. 2010;121:685-92.
10. Li LC, Yeh CC, Nojima D, et al. Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun. 2000;275:682-9.
11. Zhao L, Wang L, Jin F, et al. Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer. Breast Cancer Res Treat. 2009;117:253-9.
12. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-6.
13. Sasaki M, Tanaka Y, Perinchery G, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst. 2002;94:384-90.
14. Skliris GP, Parkes AT, Limer JL, et al. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol. 2002;197:155-252.
15. Speirs V, Skliris GP, Burdall SE, et al. Distinct expression patterns of ERa and ERb in normal human mammary gland. J Clin Pathol. 2002;55:371-4.
16. Allred DC, Harvey JM, Berado M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-68.
17. Rody A, Holtrich U, Solbach C, et al. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer. 2005;12:903-16.
18. Kim SJ, Kim TW, Lee SY, et al. CpG methylation of the ERalpha and ERbeta genes in breast cancer. Int J Mol Med. 2004;14: 289-93.
19. Walton TJ, Li G, Seth R, et al. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate. 2008;68:210-22.
20. Al-Nakhle H, Burns PA, Cummings M, et al. Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res. 2010;70:4778-84.
21. Chen GG, Zeng Q, Tse GM. Estrogen and its receptors in cancer. Med Res Rev. 2008;28:954-74.
22. Marotti JD, Collins LC, Hu R, et al. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2010;23:197-204.
23. Mehrotra J, Ganpat MM, Kanaan Y, et al. Estrogen receptor/progesterone receptor negative breast cancers of young African-American women havea higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res. 2004;10:2052-7.
24. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417-22.